COVID-19 – External Monitoring Guidelines

Posted:
1
July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.

RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.

View Guidelines

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more

Richmond Pharmacology supports Codiak BioSciences in the development of a new medicine to help patients with cutaneous T cell lymphoma.

February 3, 2021
Richmond Pharmacology were pleased to provide our sponsor, Codiak BioSciences, with positive results of its exosome therapeutic exoIL-12.
Read more

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more